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Abstract
Infectious bovine rhinotracheitis (IBR) has been assessed according to the criteria of the Animal Health
Law (AHL), in particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of
IBR to be listed, Article 9 for the categorisation of IBR according to disease prevention and control
rules as in Annex IV and Article 8 on the list of animal species related to IBR. The assessment has
been performed following a methodology composed of information collection and compilation, expert
judgement on each criterion at individual and, if no consensus was reached before, also at collective
level. The output is composed of the categorical answer, and for the questions where no consensus
was reached, the different supporting views are reported. Details on the methodology used for this
assessment are explained in a separate opinion. According to the assessment performed, IBR can be
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL. The
disease would comply with the criteria in Sections 4 and 5 of Annex IV of the AHL, for the application
of the disease prevention and control rules referred to in points (d) and (e) of Article 9(1). The
assessment here performed on compliance with the criteria as in Section 3 of Annex IV referred to in
point (c) of Article 9(1) is inconclusive. The animal species to be listed for IBR according to Article 8(3)
criteria belong to the order Artiodactyla.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
Keywords: Infectious bovine rhinotracheitis, IBR, BoHV-1, Animal Health Law, listing, categorisation,
impact
Requestor: European Commission
Question number: EFSA-Q-2016-00586
Correspondence: alpha@efsa.europa.eu
EFSA Journal 2017;15(7):4947www.efsa.europa.eu/efsajournal
Panel members: Dominique Bicout, Anette Bøtner, Andrew Butterworth, Paolo Calistri, Klaus Depner,
Sandra Edwards, Bruno Garin-Bastuji, Margaret Good, Christian Gortazar Schmidt, Virginie Michel,
Miguel Angel Miranda, Simon More, Søren Saxmose Nielsen, Mohan Raj, Liisa Sihvonen, Hans Spoolder,
Jan Arend Stegeman, Hans-Hermann Thulke, Antonio Velarde, Preben Willeberg and Christoph
Winckler.
Acknowledgements: The Panel wishes to thank David Graham for the support provided to this
scientiﬁc output.
Suggested citation: EFSA AHAW Panel (EFSA Panel on Animal Health and Welfare), More S, Bøtner A,
Butterworth A, Calistri P, Depner K, Edwards S, Garin-Bastuji B, Good M, Gortazar Schmidt C, Michel V,
Miranda MA, Nielsen SS, Raj M, Sihvonen L, Spoolder H, Stegeman JA, Thulke H-H, Velarde A, Willeberg P,
Winckler C, Baldinelli F, Broglia A, Dhollander S, Beltran-Beck B, Kohnle L, Morgado J and Bicout D, 2017.
Scientiﬁc Opinion on the assessment of listing and categorisation of animal diseases within the framework
of the Animal Health Law (Regulation (EU) No 2016/429): infectious bovine rhinotracheitis (IBR). EFSA
Journal 2017;15(7):4947, 25 pp. https://doi.org/10.2903/j.efsa.2017.4947
ISSN: 1831-4732
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited and no
modiﬁcations or adaptations are made.
Reproduction of the images listed below is prohibited and permission must be sought directly from the
copyright holder:
Figure 1 (Annex): © World Organisation for Animal Health (OIE)
The EFSA Journal is a publication of the European Food
Safety Authority, an agency of the European Union.
AHL assessment on infectious bovine rhinotracheitis (IBR)
www.efsa.europa.eu/efsajournal 2 EFSA Journal 2017;15(7):4947
Table of contents
Abstract................................................................................................................................................. 1
1. Introduction............................................................................................................................... 4
1.1. Background and Terms of Reference as provided by the requestor................................................. 4
1.2. Interpretation of the Terms of Reference...................................................................................... 4
2. Data and methodologies ............................................................................................................. 4
3. Assessments .............................................................................................................................. 4
3.1. Assessment according to Article 7 criteria..................................................................................... 4
3.1.1. Article 7(a) Disease Proﬁle .......................................................................................................... 4
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease................................................................. 4
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal populations ..................... 5
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease .................................................................... 6
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance............................... 6
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the environment............... 6
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between animals,
and, when relevant, between animals and humans ....................................................................... 7
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the Union,
and, where the disease is not present in the Union, the risk of its introduction into the Union.......... 7
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools ............................................ 8
3.1.2. Article 7(b) The impact of diseases .............................................................................................. 8
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture production and
other parts of the economy......................................................................................................... 8
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health............................................................ 9
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare .......................................................... 9
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment ............................... 9
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use in bioterrorism ............... 9
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following disease
prevention and control measures................................................................................................. 10
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities................................................................................ 10
3.1.4.2. Article 7(d)(ii) Vaccination ........................................................................................................... 12
3.1.4.3. Article 7(d)(iii) Medical treatments ............................................................................................... 12
3.1.4.4. Article 7(d)(iv) Biosecurity measures ............................................................................................ 12
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products............................................ 13
3.1.4.6. Article 7(d)(vi) Killing of animals .................................................................................................. 14
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products .................................. 14
3.1.5. Article 7(e) The impact of disease prevention and control measures............................................... 14
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the economy
as a whole ................................................................................................................................. 14
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control measures ........................ 14
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals ............................. 15
3.1.5.4. Article 7(e)(iv) The environment and biodiversity .......................................................................... 15
3.2. Assessment according to Article 5 criteria..................................................................................... 15
3.2.1. Outcome of the assessment of infectious bovine rhinotracheitis according to criteria of
Article 5(3) of the AHL on its eligibility to be listed........................................................................ 16
3.3. Assessment according to Article 9 criteria..................................................................................... 16
3.3.1. Non-consensus questions............................................................................................................ 19
3.3.2. Outcome of the assessment of criteria in Annex IV for infectious bovine rhinotracheitis
for the purpose of categorisation as in Article 9 of the AHL ........................................................... 20
3.4. Assessment of Article 8............................................................................................................... 22
4. Conclusions................................................................................................................................ 22
References............................................................................................................................................. 23
Abbreviations ......................................................................................................................................... 25
AHL assessment on infectious bovine rhinotracheitis (IBR)
www.efsa.europa.eu/efsajournal 3 EFSA Journal 2017;15(7):4947
1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and Article 8 within the Animal Health Law (AHL) framework
(EFSA AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017).
The present document reports the results of assessment on infectious bovine rhinotracheitis (IBR)
according to the criteria of the AHL articles as follows:
• Article 7: IBR proﬁle and impacts
• Article 5: eligibility of IBR to be listed
• Article 9: categorisation of IBR according to disease prevention and control rules as in Annex
IV
• Article 8: list of animal species related to IBR.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of IBR according to the Article 7 criteria of the AHL and
related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)), based on
the information contained in the fact-sheet as drafted by the selected disease scientist (see Section 2.1
of the scientiﬁc opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
IBR is caused by a virus of the order Herpesvirales, the family Herpesviridae and the species Bovine
herpesvirus-1 (BoHV-1). IBR is a disease of domestic and wild cattle (OIE, 2017). Artiodactyla (e.g.
cattle, goats, sheep, water buffaloes, camelids) may be infected with BoHV-1. Only those non-host
(bovine) species from which BoHV-1 or DNA has been isolated from ﬁeld material or following
experimental challenge by a natural route are listed below.
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
Naturally susceptible wildlife species include: red deer (Cervus elaphus) (Fr€olich et al., 2006), roe
deer (Capreolus capreolus) (Kalman and Egyed, 2005), fallow deer (Dama dama) (Kalman and Egyed,
2005), reindeer (Rangifer tarandus) (Lillehaug et al., 2003), and feral pig (Crandell et al., 1987).
Parameter 2 – Naturally susceptible domestic species (or family/orders)
Naturally susceptible domestic species include cattle (Raaperi et al., 2014; OIE, 2017), sheep
(Whetstone and Evermann, 1988; Raaperi et al., 2014), goat (Whetstone and Evermann, 1988; Tolari
et al., 1990; Raaperi et al., 2014), water buffalo (Bubalus bubalis) (Fusco et al., 2015), and pig
(Derbyshire and Caplan, 1976; Varady et al., 1994).
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Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
Experimental infection in wildlife species have been produced in deer (Mollema et al., 2005),
reindeer (Rangifer tarandus) (Thiry et al., 2006) and mule deer (Odocoileus hemionus) (Thiry et al.,
2006).
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
Experimental infection in domestic species have been produced in rabbit (Rock and Reed, 1982).
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
None recognised. The establishment of latency following infection with BoHV-1 is considered a
prerequisite for a species to act as a reservoir. Latency is not established following infection of red
deer or reindeer (Thiry et al., 2006).
Parameter 6 – Domestic reservoir species (or family/orders)
BoHV-1 is able to establish a latent infection in the trigeminal ganglia of goats and sheep from
which it can be reactivated. However, neither sheep, goats nor pigs are considered to play a role as an
alternative reservoir for BoHV-1 (Wentink et al., 1993; Hage et al., 1997; Thiry et al., 2006; Muylkens
et al., 2007). Latency, but not reactivation, has also been demonstrated in water buffaloes
(Bubalus bubalis) leaving the role of this species as a reservoir to be proven (Scicluna et al., 2010).
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/incidence
In the absence of control, prevalence of infection is typically high both at animal and herd levels.
Raaperi et al. (2014) reviewed several different prevalence surveys in Europe and found herd-level
prevalences to range from 13.4% to 100% (mean 66.3%, median 70.4%) and animal-level prevalence
to range from 12.0% to 77.5% (mean 37.7%, median 38.4%). Calves have a lower prevalence of
infection than adult cattle, although the incidence of seroconversion is higher in animals aged
< 24 months than in adult cattle.
Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
Case morbidity is variable, depending on a number of factors including the virulence of the BoHV-1
strain, resistance factors/immune status of the host and potential concurrent bacterial infection
(Muylkens et al., 2007). The outcome of infection in terms of case morbidity may range from very low
in subclinical pictures to high (up to 90%), particularly in na€ıve populations, with morbidity and case
mortality rate typically higher in neonatal and suckling calves than in adults (Wiseman et al., 1980;
Patel, 2005a; EFSA, 2006; Muylkens et al., 2007; Nandi et al., 2009; Graham, 2013; Raaperi et al.,
2014). Modelling studies from the Netherlands, however have considered that around 5% of infectious
cows are clinically affected (Vonk Noordegraaf et al., 1998; Noordegraaf et al., 2000) as subclinical
BoHV-1 infections are more common (Muylkens et al., 2007).
Mortality
Parameter 3 – Case-fatality rate
While infection with IBR can follow a subclinical course, it may also be occasionally associated with
signiﬁcant mortality, particularly associated with the introduction of BoHV-1.1 strains to Europe in the
early 1970s (Edwards, 1988; Vonk Noordegraaf et al., 1998). Case-fatality rates of up to 8% were
reported from the early outbreaks in Ireland in 1989/1990 (Gunn and Wilson, 1991) and in the United
Kingdom (Wiseman et al., 1980). A case-mortality rate of 3% was reported for the initial description of
IBR in California (Graham, 2013). Modelling studies from the Netherlands have considered a mortality
rate around 2% among clinically affected animals (Vonk Noordegraaf et al., 1998; Noordegraaf et al.,
2000).
A recent large study in Ireland (Sayers, 2017), examining the possible variables associated with the
infection in herds (positive for BoHV-1 bulk milk antibody detection), showed no association between
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infection and mortality across different age groups (calves, young stock, adults). Whole-herd mortality
counts, however, showed a marginal increase by a factor of 1.001 in BoHV-1 ELISA positive herds
(p = 0.023) (Sayers, 2017).
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
BoHV-1 is not considered zoonotic.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
No treatments available, so resistance to treatment is not applicable.
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
During acute primary infection, BoHV-1 is excreted in nasal ﬂuid over a period of 10–17 days with a
peak at 4–6 days post-infection (Nandi et al., 2009). Cattle infected with BoHV-1.1 excrete higher
titres of virus (10–100-fold greater) in nasal ﬂuids than do cattle infected with BHV-1.2b. Following
primary preputial infection, bulls may shed BoHV-1 for several days to several weeks. Infected bulls
may also shed high concentrations of the virus in semen.
Parameter 2 – Presence and duration of latent infection period
Lifelong latent infection is considered to develop in most, if not all, cattle following acute infection.
Latency may occur within the germinal centres of the pharyngeal tonsils (EFSA, 2006; Muylkens et al.,
2007; Nandi et al., 2009).
Parameter 3 – Presence and duration of the pathogen in healthy carriers
The sensory ganglia of the trigeminal and sacral nerves are considered to be the main sites of
latency following respiratory and venereal infection respectively (EFSA, 2006; Muylkens et al., 2007;
Nandi et al., 2009). Latent BoHV-1 may be reactivated in, and shed from, carrier animals
spontaneously or by a range of stressors including parturition, mating, transport, mixing, inclement
weather, concomitant infection, poor husbandry or diet and overcrowding (EFSA, 2006; Muylkens
et al., 2007; Raaperi et al., 2014). Because virus latency is a normal sequel to BoHV-1 infection, the
identiﬁcation of serologically positive animals provides a useful and reliable indicator of infection status.
With the exception of animals with maternally derived antibodies or vaccinated with dead marker
vaccine, seropositive animals are considered latently infected carriers and potential shedders of the
virus. However, it is recognised that seronegative carriers may occur as a consequence of infection in
the presence of maternally derived antibodies (EFSA, 2006; OIE, 2017).
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
Inactivation of the virus in the environment depends on factors such as temperature, pH, light,
humidity and the medium harbouring the virus, with survival enhanced by low temperature and high
relative humidity (Nandi et al., 2009). At 4°C, the virus is stable for 1 month. It is inactivated at 56°C
within 21 min, at 37°C within 10 days and at 22°C within 50 days. The virus may survive for more
than 30 days in feeds. As the virus is enveloped, it is sensitive to organic solvents such as chloroform,
ether and acetone. The virus is sensitive to many disinfectants and is readily inactivated by 0.5%
NaOH, 0.01% HgCl2, 1% chlorinated lime, 1% phenolic derivatives, 1% quaternary ammonium bases
and 10% Lugol’s iodine. Formalin (5%) inactivates BoHV-1 within 1 min.
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3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
Transmission of BoHV-1 is usually by direct contact of a susceptible animal with an infected animal
excreting virus in oronasal or genital secretions. Aerosol spread does occur but is considered to be
limited in most cases to a few metres (EFSA, 2006). An additional transmission route is via infected
semen and vertical transmission may occur in utero. BoHV-1 may also be shed in semen following a
primary or reactivated infection, with the potential of transmission following either artiﬁcial or natural
insemination. Embryo transfer may also result in transfer of BoHV-1 adsorbed to the zona pellucida.
BoHV-1 has been isolated from milk and faeces but neither source is considered to be a signiﬁcant
transmission route in the ﬁeld (EFSA, 2006).
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
Not relevant.
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
See below.
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
BoHV-1 transmits readily between cattle when introduced to a na€ıve population. An R0 value of ≥ 9
has been reported in calves (Hage et al., 1997) while R0 ≥ 7 has been reported for adult cattle (Hage
et al., 1996). In contrast, much lower R0 values for transmission from sheep to calves or between red
deer (0.1 and 0 [0–0.94; 95% one-sided CI] respectively) (Hage et al., 1997; Mollema et al., 2005).
Based on published values for R0 and the length of the infectious period (c) (7 and 10 days
respectively) (Hage et al., 1996), the transmission rate (b) is calculated as 0.7 where R0 = b 9 c.
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in EU
IBR is present in 23 EU Member States (MSs) and consequently in a signiﬁcant part of the Union.
That fact is underlined also in point 2.4 of the annual report on bovine and swine diseases for 2015
(European Commission, 2015).
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
A number of MSs, or regions thereof, are considered free of infection and have been awarded
Article 10 status as laid down by Commission Decision 2004/558/EC1. Annex II of Commission
Implementing Decision (EU) 2015/2502 lists the following countries/regions as free of BoHV-1:
Denmark, Finland, Sweden, Austria, the Federal States of Bavaria, Thuringia, Saxony, Saxony-Anhalt,
Brandenburg, Berlin and Mecklenburg-Western Pomerania in Germany and the Autonomous Province of
Bolzano in Italy.
Annex I lists the following countries/regions as having been granted additional guarantees in
respect of BoHV-1 in light of their having approved eradication programmes in place: Belgium, the
1 2004/558/EC: Commission Decision of 15 July 2004 implementing Council Directive 64/432/EEC as regards additional
guarantees for intra-Community trade in bovine animals relating to infectious bovine rhinotracheitis and the approval of the
eradication programmes presented by certain Member States. OJ L 249, 23.7.2004, p. 20–25.
2 Commission Implementing Decision (EU) 2015/250 of 13 February 2015 amending Annexes I and II to Decision 2004/558/EC
as regards the infectious bovine rhinotracheitis-free status of the Federal States of Saxony, Saxony-Anhalt, Brandenburg, Berlin
and Mecklenburg-Western Pomerania in Germany. OJ L 41, 17.2.2015, p. 43–45.
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Czech Republic, all regions of Germany except those listed above and the Regions of Friuli-Venezia
Giulia and Valle d’Aosta and the Autonomous Province of Trento in Italy.
Infection is considered to be endemic in all other MSs and MS regions.
Risk of introduction
Infection is already present in most MSs.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
A range of reliable diagnostic tools for detection of virus, viral antigens and RNA and antibodies are
available (see Section 3.1.4.1).
Control tools
Parameter 2 – Existence of control tools
Control tools have been applied successfully at both herd- and regional-/national-levels (EFSA,
2006; Muylkens et al., 2007; Raaperi et al., 2014).
Test and slaughter strategy. This has been used successfully in Finland, Sweden, Norway,
Denmark, Austria and Switzerland.
Differentiating infected from vaccinating animals (DIVA) strategy. Marker (gE-deleted)
vaccines, which are considered safe and efﬁcacious based on both experimental and ﬁeld data (European
Commission, 2000; Dispas et al., 2004, 2009; EFSA, 2006; Makoschey et al., 2007; Ampe et al., 2012),
are available and form the basis of a control strategy where initial prevalence is moderate to high. This
approach, supplemented by biosecurity measures to address risks of introduction associated with
breeding, trade and husbandry activities, can be used to reduce the initial prevalence, with remaining
positive animals being culled when prevalence falls to 5%. The efﬁcacy of this strategy, incorporating
marker vaccination, has also been demonstrated in the ﬁeld where it has been incorporated into
successful national eradication programmes (Commission Implementing Decision (EU) 2015/250).
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
The disease is considered to be present in all non-free MS/regions, being endemic in the absence
of appropriate controls. Some MSs and regions have Commission-approved programmes for the control
and eradication of the disease and therefore may have a lower prevalence than that typically present
in the absence of such programmes. MSs to which the additional guarantees for approved eradication
programmes for IBR as deﬁned in Commission Decision 2004/558/EC in accordance with Article 10 of
Council Directive 64/432/EEC3 apply are Austria, Denmark, Finland, Germany and Sweden. In Italy,
these guarantees apply in the Region Valle d’Aosta and Autonomous Province of Bolzano and in the
United Kingdom in Jersey.
MSs to which the additional guarantees for IBR apply in accordance with Article 9 of Council
Directive 64/432/EEC are Belgium, Czech Republic and Luxembourg. In Italy they apply in the Region
Friuli-Venezia Giulia and in the Autonomous Province of Trento.
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
BoHV-1 may cause production losses through its impact on health and welfare, manifest as
respiratory (infectious bovine rhinotracheitis (IBR)) and venereal disease (infectious pustular
3 Council Directive 64/432/EEC of 26 June 1964 on animal health problems affecting intra-Community trade in bovine animals
and swine. OJ 121, 29.7.1964, pp. 1977–2012.
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vulvovaginitis/balanoposthitis (IPV)/(IPB); reduced fertility and abortion (Graham, 2013)) and a
reduction in milk yield. Limited data are available to quantify the associated losses in the ﬁeld.
Annual losses in the UK due to the disease and its treatment were estimated at up to £3.1 million
in 2005, with the highest proportion of these accounted for by mortality/premature culling, followed by
weight loss (Bennett and Ijpelaar, 2005). A more extensive study in Ireland estimated a reduced
production of 250 L/year for multiparous cows in herds testing positive for antibodies in bulk milk tank
samples (Sayers, 2017). Beside the reduced milk production, minor effects on herd fertility and
mortality were identiﬁed, adding to the growing evidence that subclinical BoHV-1 can result in ongoing
losses in dairy herds (Sayers, 2017).
Losses due to a drop in milk production associated with subclinical infection were estimated at
approximately 9.5 L over an infectious period of 14 days during a subclinical bovine herpesvirus 1
infection on a dairy farm (Hage et al., 1998). Outbreaks in semen collection centres can be very costly,
requiring destruction of all bulls in the centre (Raaperi et al., 2014).
Modelling of data from 133 herds in the Netherlands indicated an average loss of 0.92 kg of milk
per cow per day over a 9-week period following infection (van Schaik et al., 1999). Modelling of data
for a herd with a subclinical outbreak in the UK reported an estimated reduction of milk yield in
seropositive compared with seronegative cows of 2.6 kg/day over a two-year period (Statham et al.,
2015).
Parameters used in other modelling studies have included a reduction in milk yield of 263 kg and a
50% reduction in milk yield for a 3-week period in clinically affected cows (Vonk Noordegraaf et al.,
1998; Noordegraaf et al., 2000). A 0.25% abortion rate in infectious cows and reductions in growth of
100% and 50% for 3 weeks and 0.5 weeks following clinical and subclinical infection respectively have
also been used for modelling studies (Noordegraaf et al., 2000).
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Not relevant as infection is not zoonotic.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
Clinical signs may vary from inapparent to death, depending on a variety of factors including the
strain of virus, with BoHV-1 subtype 1 generally being associated with more severe clinical outcomes,
host factors and inter-current infections. Uncomplicated infections generally resolve in 7–14 days
(Bosch et al., 1996; Patel, 2005a,b; Nandi et al., 2009).
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
None identiﬁed.
Parameter 2 – Mortality in wild species
No evidence of mortalities in wild species.
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
The pathogen can survive for short periods in the environment but has not been associated with
mortalities in wildlife.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
CFSPH (http://www.cfsph.iastate.edu/DiseaseInfo/): No
OIE (http://www.oie.int/animal-health-in-the-world/oie-listed-diseases-2016/): Yes
Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
(http://www.australiagroup.net/en/human_animal_pathogens.html): No
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Parameter 3 – Included in any other list of potential bio- agro-terrorism agents
None identiﬁed.
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
A range of direct (agent identiﬁcation) and indirect (immune response) test methods for BoHV-1
are described in The OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (OIE, 2017)
(Table 1). Within Europe, availability of laboratories offering tests for both agent identiﬁcation and
detection of the immune response is high, with these commonly accredited to ISO 17025. Kits are
readily available commercially. In some countries, including Germany (https://www.fli.de/en/services/
licensing-authority/) and Belgium (http://www.coda-cerva.be/index.php?option=com_content&view=
article&id=376%3Acertifications-des-reactifs-de-diagnostiques&catid=194%3Acontrole-de-kits&Itemid=
369&lang=en) protocols for approval of diagnostic kits for use in eradication programmes are in place.
It is recommended that these are validated against EU strong positive (EU1), weak positive (EU2) and
negative (EU3) sera (or derived national standards of equivalent potency).
Serological tests may be used for a variety of purposes, including to diagnose acute infection (using
paired serum samples), to demonstrate freedom from infection for international trade, to determine
prevalence of infection for seroepidemiological purposes and to support eradication programmes and
subsequent surveillance. Annex III of Commission Decision 2004/558/EC lays down how these tests
may be used to acquire and maintain a BoHV-1-free status for holdings in countries or regions with
either an approved eradication programme or a recognised free status.
Table 1: Performance characteristics and comments thereon for diagnostic tests (EFSA, 2006; OIE,
2017)
Agent identiﬁcation
Method
Commonly
tested matrices
Analytical
sensitivity
Comments
Virus isolation Nasal, ocular and
genital swabs,
tissues, semen*
< 1–5 TCID50/mL
(EFSA, 2006)
Historically considered the reference standard
but less commonly used now due to issues of
time, cost and requirement for cell culture
Toxicity to cell cultures can be an issue,
especially with semen
Nucleic acid detection
by (real time) PCR
Nasal, ocular and
genital swabs,
tissues, semen*
< 10 genome
copies (EFSA, 2006)
Can also be used to detect DNA associated
with latent infection
Use of appropriate primers allows
differentiation between wild type and gE-
deleted vaccine strains
Use of appropriate primers allows
differentiation between BoHV-1 and other
related alphaherpesviruses
High analytical sensitivity, with sensitivity
similar to, or exceeding virus isolation
Appropriate controls necessary to avoid either
false negative or false positive results
Antigen detection by
ELISA
Nasal, ocular and
genital swabs
104–105 TCID50
(EFSA, 2006)
More rapid than virus isolation but a lower
analytical and diagnostic sensitivity
Immunoﬂuorescent
antibody testing
Nasal, ocular and
genital swabs
Lower than virus
isolation (OIE,
2017)
More rapid than virus isolation but a lower
analytical and diagnostic sensitivity
Immunohistochemistry Tissues Lower than virus
isolation (OIE,
2017)
More rapid than virus isolation but a lower
analytical and diagnostic sensitivity
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Effectiveness
Parameter 2 – Se and Sp of diagnostic test
Virus isolation and polymerase chain reaction (PCR) are considered to have a high Se and Sp.
Virus neutralisation test (VNT) is considered a sensitive and speciﬁc assay for detection of
antibodies to BoHV-1 in serum, being considered historically to be the reference standard. gB
enzyme-linked immunosorbent assays (ELISAs) are also considered highly sensitive, which may be
problematic because some weak positive gB ELISA results cannot be conﬁrmed by alternative methods
(VNT, indirect ELISA). Indirect ELISAs are considered to be somewhat less sensitive when applied to
sera, based on the published results of an inter-laboratory ring trial (Kramps et al., 2004) which
reported the Se/Sp values presented in Table 1. In contrast, indirect ELISAs were reported to be
superior for testing of milk samples in this study. While these same conclusions remain accepted today,
the reported performance characteristics should be interpreted with caution. First, the total number of
samples tested was relative low, secondly the report included results for both commercial and in-house
ELISA kits (with the former performing better) and ﬁnally the indirect kits used in the study have now
largely been superseded by a new generation of highly sensitive kits (EFSA, 2006). In regard to gE
ELISAs, much higher Se values (99–100%) have been reported (EFSA, 2006) while newer test
methodologies, formats and antibody concentration techniques offer the possibility of increased Se
values (Bertolotti et al., 2015; Casarin et al., 2016).
While the speciﬁcity of all ELISAs is considered to be high, non-speciﬁc reactions may occur for
several reasons due to batch variation of kits, early testing after collection (freshness phenomenon),
recent vaccination (vaccination phenomenon) and sub-optimal sample quality (OIE, 2017). Cross-
reactivity with bovine herpesvirus 2 has been proposed as the cause of epidemiologically non-feasible
singleton serological reactors (B€ottcher et al., 2012). Close antigenic and genetic relationships exist
between BoHV-1 and other ruminant alphaherpesviruses including BoHV-5, caprine herpesvirus 1
(CpHV-1), cervid herpesvirus 1 (CvHV-1; red deer), cervid herpesvirus 2 (CvHV-2; reindeer), bubaline
Detection of immune response
Method
Commonly
tested
matrices
Diagnostic Se/Sp Comments
Virus
neutralisation*
Serum 93%/96% (Kramps
et al., 2004)
Historically considered the reference standard, but
time-consuming and costly
Does not discriminate between ﬁeld and vaccine
antibodies
Antibody response detectable 9–11 days post-
infection
gB ELISA* Serum, milk,
bulk tank milk
96%/99% (serum)
81%/83% (milk)
(Kramps et al.,
2004)
Do not discriminate between ﬁeld and vaccine
antibodies
Antibody response detectable 9–11 days post-infection
Can be more sensitive than VN, presenting problems
in conﬁrmation
Indirect ELISA* Serum, milk,
bulk tank milk
87%/99% (serum)
98%/93% (milk)
(Kramps et al.,
2004)
Do not discriminate between ﬁeld and vaccine
antibodies
Antibody response detectable 9–11 days post-infection
Can detect a single positive milk sample in a pool of
50
gE ELISA* Serum, milk,
bulk tank milk
72%/92% (serum)
58%/88% (milk)
(Kramps et al.,
2004)
Discriminates between ﬁeld and vaccine (marker)
antibodies
Lower sensitivity than gB ELISA in serum and milk
reﬂecting lower immunogenicity of gB
Seroconversion may not be detected until 21–35 days
post-infection
Returns a negative bulk tank milk test result when
seroprevalence falls below 10–15%
Current lack of conﬁrmatory test
TCID: tissue culture infectious dose, 50%; PCR: polymerase chain reaction; ELISA: enzyme-linked immunosorbent assay.
*: Prescribed test for international trade.
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herpesvirus 1 (BuHV-1) and elk herpesvirus 1 (ElkHV-1), potentially resulting in serological cross-
reactions (Thiry et al., 2006; Raaperi et al., 2014; OIE, 2017). Reports of serological evidence of
infection (particularly in wildlife, including nyala (Tragelaphus angasi), bushbuck (Tragelaphus scriptus),
kudu (Tragelaphus strepsiceros), eland (Taurotragus oryx), African buffalo (Syncercus caffer), sable
(Hippotragus niger), impala (Aepyceros melampus), wildebeest (Connochaetes taurinus), tsessebe
(Damaliscus lunatus) and giraffe (Giraffa camelopardalis) (Anderson and Rowe, 1998) in the absence
of viral isolates must therefore be interpreted with caution.
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
See Table 1.
3.1.4.2. Article 7(d)(ii) Vaccination
Availability
Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)
A range of live and inactivated vaccines are available, including products with DIVA properties
(based on deletion of the gene encoding glycoprotein E), the use of which plays an important role in
the approved control and eradication programmes in place in a number of MSs (Patel, 2005a,b; EFSA,
2006; Muylkens et al., 2007; Raaperi et al., 2014).
Parameter 2 – Availability/production capacity (per year)
IBR vaccines are widely available in the EU and worldwide, but speciﬁc data on production
capacities are lacking.
Effectiveness
Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to
disease)
All vaccines licensed in Member States must satisfy the requirements of the IBR Monograph of the
European Pharmacopoeia (OIE, 2017). Vaccines with DIVA properties are considered safe and
efﬁcacious based on data from experimental and ﬁeld studies (European Commission, 2000; Dispas
et al., 2004, 2009; EFSA, 2006; Makoschey et al., 2007; Ampe et al., 2012). Ultimately their efﬁcacy in
the ﬁeld has been demonstrated by their incorporation into successful national eradication programmes
(Commission Implementing Decision (EU) 2015/250). Summaries of product characteristics generally
contain claims in relation to a reduction in clinical signs and duration of virus shedding (for further
details see http://www.ema.europa.eu/ema or http://www.hpra.ie/homepage/veterinary). Some
products are also licensed for use to reduce the incidence of abortions associated with infection with
BoHV-1.
Parameter 4 – Duration of protection
Duration of protection is dependent on the product used and the age and maternal antibody status
of the vaccinated animal. Excluding calves, the duration of protection (and the booster interval) is
commonly 6 months, although for some vaccination regimes this is extended to 12 months.
Feasibility
Parameter 5 – Way of administration
Depending on the product, these may be administered by the intramuscular, subcutaneous or
intranasal routes.
3.1.4.3. Article 7(d)(iii) Medical treatments
No antiviral drugs are available for treating infection with BoHV-1.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
The key risk factors for introduction of BoHV-1 are known (EFSA, 2006; Raaperi et al., 2014),
falling broadly under the headings of trade in (and movement of) animals, fomites and personnel,
semen, ova and embryos, and airborne spread.
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Availability
Parameter 1 – Available biosecurity measures
Measures to address the routes of introduction are available. Quarantine, in conjunction with
appropriate serological testing can reduce the risk associated with trade, particularly if supplemented
with knowledge of the status of introduced animals and their source herds. These measures are
further enhanced for countries with approved national or regional control and eradication programmes
by additional guarantees with respect to trade (Council Directive 64/432/EEC). Contact of animals with
those in other herds can be avoided or restricted by measures including a non-return policy and not
participating in shows (or implementation of quarantine) and adequate boundary fencing. Aerosol
spread may occur over very short distances. The R0 is reported to fall below 1.0 at a distance of 4.4 m
(Mars et al., 2000).
Risks associated with fomites and personnel can be addressed through appropriate disinfection
procedures, limiting visitors and their degree of contact with cattle and applying appropriate
disinfection procedures and/or provision of farm-speciﬁc boots and clothing.
Bulls entering semen-collection centres approved for intracommunity trade in MSs must meet
quarantine and subsequent monitoring requirements, with semen and embryos imported from third
countries subject to similar requirements (Mars et al., 2000).
Treatment of embryos prior to implantation can inactivate absorbed virus (EFSA, 2006).
Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
These measures are generally considered effective. However, the existence of seronegative latent
carriers and the suboptimal sensitivity of diagnostic tests to detect antibodies to gE mean that
quarantine and surveillance measures may not always be fully effective (EFSA, 2006; Raaperi et al.,
2014).
Feasibility
Parameter 3 – Feasibility of biosecurity measure
These measures are considered feasible, forming the basis of the biosecurity measures that
underpin approved control and eradication programmes and trade/importation of semen and embryos.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
The key restriction measure relates to the movement of latently infected carrier animals. This is
available through the application of serological screening. These measures are further enhanced for
countries with approved national or regional control and eradication programmes by additional
guarantees with respect to trade (Council Directive 64/432/EEC).
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread
The measures are considered effective, having formed the basis of the movement controls that
underpin approved control and eradication programmes. However, the existence of seronegative latent
carriers and the sub-optimal sensitivity of diagnostic tests to detect antibodies to gE mean that
quarantine and surveillance measures may not always be fully effective (EFSA, 2006; Raaperi et al.,
2014).
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
The measures are considered feasible, having formed the basis of the movement controls that
underpin approved control and eradication programmes.
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3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animals
Latently infected carrier animals are not excluded from the food chain subject to passing
appropriate ante-mortem and post-mortem inspection. Therefore slaughter is normally carried out in
abattoirs.
Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping
spread of the disease
Culling of seropositive animals to achieve eradication at farm level is effective when prevalence has
fallen to low levels, but is not normally practiced in the face of an outbreak.
Feasibility
Parameter 3 – Feasibility of killing animals
Disposal of carrier animals through abattoirs is routinely practiced.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Carcasses and by-products of otherwise healthy carrier animals are disposed of through the abattoir
system, entering the food chain. This procedure has been considered as effective.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
In general, there is a lack of reliable published disease data for economic analysis (Bennett and
Ijpelaar, 2005). In one modelling study, a range of control strategies for Dutch dairy herds were
evaluated (Vonk Noordegraaf et al., 1998). The optimal strategy achieved a national prevalence of
gE-seropositive cattle of 5% after 241 weeks. Programme costs to this point were estimated at Dﬂ
219 million (equivalent to €99.5 million at 2.2 Dﬂ/euro). Of these costs, 62.5% was attributable to
vaccination, with the remainder due to diagnosis (10.5%), monitoring (7.8%) and culling (19.2%).
Additional costs of dealing with the remaining 5% seropositive animals were attributed to testing
(€2.7 million) and culling (€25 million), with a payback period of 397 weeks.
Parameter 2 – Cost of eradication (culling, compensation)
See Parameter 1 above.
Parameter 3 – Cost of surveillance and monitoring
Countries or regions that achieved eradication and acquired Article 10 status have ongoing
surveillance costs based on the requirements of Commission Decision 2004/558/EC.
Parameter 4 – Trade loss (bans, embargoes, sanctions) by animal product
Data are not available.
Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to
business amount of the sector
The current implementation/completion of control and eradication programmes by a number of
Member States reﬂects the importance attached to the disease.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
The control and eradication programmes that have either been completed or are currently
underway in a number of MSs seem to have good societal acceptance.
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3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
Control measures which result in the control and eradication of infection are anticipated to have a
beneﬁcial impact on the welfare of domestic animals and a high degree of societal acceptance.
Parameter 2 – Wildlife depopulation as control measure
Depopulation of wildlife has not been implemented as a control measure for BoHV-1.
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
Biocides and medicinal drugs are not used for control of BoHV-1.
Biodiversity
Parameter 2 – Mortality in wild species
Control measures are not anticipated to result in mortality in wild species.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about IBR (Table 2). The expert judgement was based on Individual and Collective Behavioural
Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW
Panel, 2017). Experts have been provided with information of the disease fact-sheet mapped into
Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or
‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 11. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 2: Outcome of the expert judgement on the Article 5 criteria for infectious bovine
rhinotracheitis
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof exist
in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due to
its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective and
proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal
health, or poses or could pose a signiﬁcant risk to public health due to its zoonotic
character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger to
public and/or animal health in the Union
na
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
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3.2.1. Outcome of the assessment of infectious bovine rhinotracheitis according
to criteria of Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 2, IBR complies
with all criteria of the ﬁrst set and with two criteria of the second set, therefore it is considered eligible
to be listed as laid down in Article 5 of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about IBR (Tables 3, 4, 5, 6 and 7). The expert judgement was
based on ICBA approach described in detail in the opinion on the methodology. Experts have been
provided with information of the disease fact-sheet mapped into Article 9 criteria (see supporting
information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement on each criterion
of Article 9, and the reasoning supporting their judgement. The minimum number of judges in the
judgement was 11. The expert judgement was conducted as described in the methodological opinion
(EFSA AHAW Panel, 2017). For details on the interpretation of the questions, see Appendix B of the
methodological opinion (EFSA AHAW Panel, 2017).
B(iv) The disease has the potential to generate a crisis or the disease agent could
be used for the purpose of bioterrorism
N
B(v) The disease has or could have a signiﬁcant negative impact on the
environment, including biodiversity, of the Union
N
Colour code: green = consensus (Yes/No), red = not applicable (na), i.e. insufﬁcient evidence or irrelevant to judge.
Table 3: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for infectious bovine rhinotracheitis (CI = current impact;
PI = potential impact)
Criteria to be met by the disease:
the disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present in only in a very limited part of the territory of
the Union
N
2.1 The disease is highly transmissible Y
2.2 There be possibilities of airborne or waterborne or vector-borne spread N
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates N
At least one criterion to be met by the disease:
in addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
NC
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
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Table 4: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for infectious bovine rhinotracheitis (CI = current impact;
PI = potential impact)
Criteria to be met by the disease:
the disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are free
of the disease
Y
2.1 The disease is moderately to highly transmissible Y
2.2 There be possibilities of airborne or waterborne or vector-borne spread N
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality NC
At least one criterion to be met by the disease:
in addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
NC
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large numbers
of animals
NC
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to
those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to
those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
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Table 5: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for infectious bovine rhinotracheitis (CI = current impact;
PI = potential impact)
Criteria to be met by the disease:
the disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character
Y
2.1 The disease is moderately to highly transmissible Y
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
AND often the most observed effect of the disease is production loss
NC
At least one criterion to be met by the disease: in addition to the criteria set out above at points 1–2.4,
the disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related
to its direct impact on certain types of animal production systems
NC
4(PI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related
to its direct impact on certain types of animal production systems
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
Table 6: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for infectious bovine rhinotracheitis
Criteria to be met by the disease:
the disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated
by measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
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3.1.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in the form of tables (Tables 8, 9,
10 and 11). The proportion of Y, N or `na0 answers are reported, followed by the list of different
supporting views for each answer.
Reasoning supporting the judgement
Supporting Yes for 2.4 (cat.B):
• High morbidity (up to 90%) and case-fatality rate ranging from 2% to 8% in na€ıve populations
are reported.
Supporting Yes for 2.4 (cat.C):
• Production losses (e.g. milk losses) are often the sole signs of infection observed.
Reasoning supporting the judgement
Supporting Yes for 4 (cat.A,B):
• The economic impact due to milk production losses can be considered signiﬁcant at EU level.
Table 7: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for infectious bovine rhinotracheitis
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal
welfare, human health, the economy, society or the environment (If a disease fulﬁls the
criteria as in Article 5, thus being eligible to be listed, consequently category E would
apply.)
Y
Colour code: green = consensus (Yes/No).
Table 8: Outcome of the expert judgement related to criterion 2.4 of Article 9
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
2.4(cat.B) The disease may result in high morbidity with in general low
mortality
NC 64 0 0
2.4(cat.C) The disease usually does not result in high morbidity and has
negligible or no mortality AND often the most observed effect of
the disease is production loss
NC 36
NC: non-consensus; number of judges: 11.
Table 9: Outcome of the expert judgement related to criterion 4(CI) of Article 9
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
4(cat. A,B) The disease has a signiﬁcant impact on the economy of the
Union, causing substantial costs, mainly related to its direct
impact on the health and productivity of animals
NC 36 9 0
4(cat.C) The disease has a signiﬁcant impact on the economy of the
Union, mainly related to its direct impact on certain types of
animal production systems
NC 55
NC: non-consensus; number of judges: 11.
AHL assessment on infectious bovine rhinotracheitis (IBR)
www.efsa.europa.eu/efsajournal 19 EFSA Journal 2017;15(7):4947
Supporting Yes for 4 (cat.C):
• There may be losses for the dairy sector, but only during the clinical period which is relatively
short.
• The economic impact cannot be considered signiﬁcant for the Union as a whole, also considering
that vaccination is available and some MSs managed to eradicate or control the disease.
• There is a signiﬁcant impact on the sector relating to semen collection and artiﬁcial
insemination.
Reasoning supporting the judgement
Supporting Yes:
• Morbidity can be 100% and mortality 10%, and while uncomplicated cases of disease last
5–10 days only, about 10% of affected animals may also experience loss of body condition and
pneumonia following the acute stage. Even in the acute stage, animal welfare appears to be
compromised with fever, respiratory symptoms, fever, drop in milk yield, and ulcerations of the
nasal mucosa (Nandi et al., 2009).
Supporting No:
• In endemic situation, which is the case in the largest part of the EU, the impact on animal
welfare seems to be not signiﬁcant.
Reasoning supporting the judgement
Supporting Yes:
• Clinical signs may vary from inapparent to death, depending on a variety of factors including
the strain of virus, with BoHV-1 subtype 1 generally being associated with more severe clinical
outcomes.
• The impact on animal welfare could be signiﬁcant in the case the disease is introduced in free
areas.
Supporting No:
• The potential impact on animal welfare in absence of control measures would not be different
from the current situation, given the situation of endemicity of the disease.
3.3.2. Outcome of the assessment of criteria in Annex IV for infectious bovine
rhinotracheitis for the purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered to ﬁt in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
Table 10: Outcome of the expert judgement related to criterion 5(b)(CI) of Article 9
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
5(b) The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
NC 9 91 0
NC: no consensus; Number of judges: 11.
Table 11: Outcome of the expert judgement related to criterion 5(b)(PI) of Article 9
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
5(b) The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
NC 82 18 0
NC: non-consensus; number of judges: 11.
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one of the second set of criteria from 3 to 5(d) as shown in Tables 3–7. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
With respect to different type of impact where the assessment is divided into current and potential
impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’ and the
assessment is inconclusive if, in case of no ‘Y’, at least one outcome is ‘NC’.
A description of the outcome of the assessment of criteria in Annex IV for IBR for the purpose of
categorisation as in Article 9 of the AHL is presented in Table 12.
According to the assessment here performed, IBR complies with the following criteria of the
Sections 1 to 5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a) to (e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment IBR complies with criteria 2.1 and 2.3, but not
with criteria 1, 2.2 and 2.4. To be eligible for category A, a disease needs to comply
additionally with one of the criteria of the second set (3, 4, 5a–d) and IBR complies with
criterion 4, but not with criteria 3, 5a, 5c and 5d and the assessment is inconclusive on
compliance with criterion 5b.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment IBR complies with criteria 1, 2.1 and 2.3, but
not with criterion 2.2 and the assessment is inconclusive on compliance with criterion 2.4. To
be eligible for category B, a disease needs to comply additionally with one of the criteria of
the second set (3, 4, 5a–d) and IBR complies with criterion 4, but not with criteria 3, 5a, 5c
and 5d and the assessment is inconclusive on compliance with criterion 5b.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment IBR complies with criteria 1, 2.1, 2.2 and 2.3
and the assessment is inconclusive on compliance with criterion 2.4. To be eligible for
category C, a disease needs to comply additionally with one of the criteria of the second set
(3, 4, 5a–d) and IBR does not comply with criteria 3, 4, 5a, 5c and 5d and the assessment is
inconclusive on compliance with criterion 5b.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or 5
of Annex IV of the AHL and with the speciﬁc criterion D of Section 4, with which IBR complies.
Table 12: Outcome of the assessment of criteria in Annex IV for IBR for the purpose of
categorisation as in Article 9 of the AHL (CI = current impact; PI = potential impact)
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5, with which IBR complies.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
infectious bovine rhinotracheitis. The Article 8(3) criteria are about animal species to be listed, as it
reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.4 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the animal species to be listed for infectious bovine rhinotracheitis
according to the criteria of Article 8(3) of the AHL are as displayed in Table 13.
4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, IBR complies with all criteria of the ﬁrst set and
with two criteria of the second set and therefore can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, IBR meets the criteria as in Sections 4 and 5 of
Annex IV of the AHL, for the application of the disease prevention and control rules referred to
in points (d) and (e) of Article 9(1) of the AHL. According to the assessment here performed, it
is inconclusive whether IBR complies with the criteria as in Section 3 of Annex IV of the AHL,
for the application of the disease prevention and control rules referred to in point (c) of
Table 13: Main animal species to be listed for IBR according to criteria of Article 8 (source: data
reported in Section 3.1.1.1)
Order Family Genus/species
Susceptible Artiodactyla Camelidae Camelus dromedarius, Camelus bactrianus, Lama glama,
Vicugna pacos, Lama guanicoe, Vicugna vicugna
Cervidae Cervus elaphus, Capriolus capriolus, Dama dama,
Rangifer tarandus, Odocoileus hemionus
Suidae Sus scrofa
Bovidae Bos taurus, Bubalus bubalis, Capra hircus, Ovis aries
Reservoir None
Vectors None
4 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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Article 9(1) of the AHL. Compliance of infectious bovine rhinotracheitis with the criteria as in
Section 3 is dependent on a decision on criterion 2.4.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list
of animal species that should be considered candidates for listing in accordance with Article 8 of the
AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for IBR according to Article 8(3) of the AHL are several species belonging to the families
Bovidae, Cervidae, Camelidae and Suidae, as reported in Table 14 in Section 3.4 of the present
document.
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Abbreviations
AHAW EFSA Panel on Animal Health and Welfare
AHL Animal Health Law
BoHV-1 bovine herpesvirus-1
BuHV bubaline herpesvirus
CFSPH Center for Food Security and Public Health
CITES Convention on International Trade in Endangered Species of Wild Fauna and Flora
CpHV caprine herpesvirus
CvHV cervid herpesvirus
ELISA enzyme-linked immunosorbent assay
ElkHV elk herpesvirus
IBR infectious bovine rhinotracheitis
ICBA Individual and Collective Behavioural Aggregation
IPB infectious pustular balanoposthitis
IPV infectious pustular vulvovaginitis
IUCN International Union for Conservation of Nature
OIE World Organization for Animal Health
PCR polymerase chain reaction
TCID tissue culture infectious dose, 50%
ToR Terms of Reference
VNT virus neutralisation test
AHL assessment on infectious bovine rhinotracheitis (IBR)
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